DEA Cannabis Rescheduling Hearing Faces Transparency Push

Cannabis industry stakeholders push for unprecedented transparency as media organizations petition the DEA's administrative law judge to allow public livestreaming of upcoming marijuana rescheduling hearings. The request underscores growing pressure on federal regulators to conduct the historic proceedings with full public visibility.

The rescheduling process represents the most consequential federal cannabis policy shift in decades, with potential ramifications across the $30 billion U.S. cannabis market. Moving marijuana from Schedule I to Schedule III would fundamentally alter tax treatment for cannabis companies, eliminating the 280E tax burden that currently prevents businesses from deducting standard operating expenses.

Public access to these proceedings carries particular weight given the financial stakes involved. Major multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) stand to benefit substantially from rescheduling through improved profit margins and enhanced banking access. The administrative hearing process typically operates behind closed doors, making this transparency push unusual for federal drug scheduling decisions.

The petition reflects broader industry frustration with the opaque nature of federal cannabis policy development. Investors have watched cannabis stocks fluctuate wildly on rescheduling speculation throughout 2024, with limited concrete information about timing or likelihood of policy changes. Live proceedings would provide real-time insight into regulatory thinking and potential outcomes.

Whether the DEA approves public streaming remains uncertain, but the request signals intensifying scrutiny of federal cannabis policy machinery. The administrative law judge's decision on transparency could set precedent for future drug scheduling proceedings while demonstrating the government's commitment to public accountability in reshaping decades-old prohibition policies.